Olfactory dysfunction in LRRK2 G2019S mutation carriers

被引:51
|
作者
Saunders-Pullman, R. [1 ,2 ]
Stanley, K. [1 ]
Wang, C. [3 ]
San Luciano, M. [1 ]
Shanker, V. [1 ,2 ]
Hunt, A. [1 ]
Severt, L. [1 ]
Raymond, D. [1 ]
Ozelius, L. J. [4 ,5 ]
Lipton, R. B. [2 ]
Bressman, S. B. [1 ,2 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Neurol, New York, NY 10003 USA
[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[3] Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA
[4] Mt Sinai Sch Med, Dept Genet, New York, NY USA
[5] Mt Sinai Sch Med, Dept Genom Sci & Neurol, New York, NY USA
关键词
FAMILIAL PARKINSONS-DISEASE; EARLY-ONSET; IDENTIFICATION; PATHOLOGY; HYPOSMIA; STAGE;
D O I
10.1212/WNL.0b013e318227041c
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Olfactory dysfunction is an established nonmotor feature of idiopathic Parkinson disease (PD), which may precede disease onset. Olfaction is likely disturbed in patients with PD with leucine-rich repeat kinase (LRRK2) G2019S mutations, although the degree of impairment is debated. It is also unclear whether mutation carriers who have not yet manifested with PD have olfactory disturbances. Methods: Thirty-one subjects with LRRK2 G2019S mutation-related PD (PD-manifesting carriers [PD-MC]), 30 subjects with PD without mutations (PD noncarriers [PD-NC]), 28 mutation carrier family members (nonmanifesting carriers [NMC]), and 46 controls completed the University of Pennsylvania Smell Identification Test (UPSIT). Generalized estimating equations were applied to determine whether olfactory score was associated with PD and LRRK2 mutation status. Results: As expected, having PD was associated with impaired olfaction regardless of LRRK2 mutation status. More importantly, however, impaired olfaction was increased overall in LRRK2 carriers both with and without PD, though the impairment was only present in a subset of NMCs. Compared to controls, the mean score was lower among NMC (difference = -3.518, p = 0.006), MC (difference = -7.677, p < 0.0001), and idiopathic PD (PD-NC) (difference = -13.810, p < 0.0001). Olfaction was better among MC (PD-MC) than non-LRRK2 PD (PD-NC) (difference = 6.13, p = 0.0012). Group differences from the continuous analysis were maintained in dichotomous analysis stratifying at 15th percentile for age and gender. Conclusion: Olfaction is impaired in LRRK2 G2019S-mutation related PD, although less overall than other PD. Further, olfaction is impaired in a subset of LRRK2 NMC, suggesting that olfaction may be a marker for development of PD in this group, and that longitudinal studies are warranted. Neurology (R) 2011; 77: 319-324
引用
收藏
页码:319 / 324
页数:6
相关论文
共 50 条
  • [41] Cellular processes associated with LRRK2 function and dysfunction
    Wallings, Rebecca
    Manzoni, Claudia
    Bandopadhyay, Rina
    FEBS JOURNAL, 2015, 282 (15) : 2806 - 2826
  • [42] Application of the Movement Disorder Society Prodromal Criteria in Healthy G2019S-LRRK2 Carriers
    Mirelman, Anat
    Saunders-Pullman, Rachel
    Alcalay, Roy N.
    Shustak, Shiran
    Thaler, Avner
    Gurevich, Tanya
    Raymond, Deborah
    Mejia-Santana, Helen
    Orbe Reilly, Martha
    Ozelius, Laurie
    Clark, Lorraine
    Gana-Weisz, Mali
    Bar-Shira, Anat
    Orr-Utreger, Avi
    Bressman, Susan B.
    Marder, Karen
    Giladi, Nir
    MOVEMENT DISORDERS, 2018, 33 (06) : 966 - 973
  • [43] Evidence for prehistoric origins of the G2019S mutation in the North African Berber population
    Ben El Haj, Rafiqua
    Salmi, Ayyoub
    Regragui, Wafa
    Moussa, Ahmed
    Bouslam, Naima
    Tiber, Houyam
    Benomar, Ali
    Yahyaoui, Mohamed
    Bouhouche, Ahmed
    PLOS ONE, 2017, 12 (07):
  • [44] A novel LRRK2 mutation in a mainland Chinese patient with familial Parkinson's disease
    Wang, Lei
    Guo, Ji-feng
    Nie, Li-luo
    Xu, Qian
    Zuo, Xing
    Sun, Qi-ying
    Yan, Xin-xiang
    Tang, Bei-sha
    NEUROSCIENCE LETTERS, 2010, 468 (03) : 198 - 201
  • [45] A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations
    Lohmann, Ebba
    Leclere, Laurence
    De Anna, Francesca
    Lesage, Suzanne
    Dubois, Bruno
    Agid, Yves
    Duerr, Alexandra
    Brice, Alexis
    PARKINSONISM & RELATED DISORDERS, 2009, 15 (04) : 273 - 276
  • [46] LRRK2 Modulates Vulnerability to Mitochondrial Dysfunction in Caenorhabditis elegans
    Saha, Shamol
    Guillily, Maria D.
    Ferree, Andrew
    Lanceta, Joel
    Chan, Diane
    Ghosh, Joy
    Hsu, Cindy H.
    Segal, Lilach
    Raghavan, Kesav
    Matsumoto, Kunihiro
    Hisamoto, Naoki
    Kuwahara, Tomoki
    Iwatsubo, Takeshi
    Moore, Landon
    Goldstein, Lee
    Cookson, Mark
    Wolozin, Benjamin
    JOURNAL OF NEUROSCIENCE, 2009, 29 (29) : 9210 - 9218
  • [47] Atypical tauopathy in a patient with LRRK2-G2019S mutation and tremor-dominant Parkinsonism
    Ruffmann, C.
    Giaccone, G.
    Canesi, M.
    Bramerio, M.
    Goldwurm, S.
    Gambacorta, M.
    Rossi, G.
    Tagliavini, F.
    Pezzoli, G.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2012, 38 (04) : 382 - 386
  • [48] Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk
    Lesniak, Robert K.
    Nichols, R. Jeremy
    Montine, Thomas J.
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [49] Epitope mapping of antibodies to alpha-synuclein in LRRK2 mutation carriers, idiopathic Parkinson disease patients, and healthy controls
    Alvarez-Castelao, Beatriz
    Gorostidi, Ana
    Ruiz-Martinez, Javier
    Lopez de Munain, Adolfo
    Castano, Jose G.
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6
  • [50] Targeting LRRK2 mutations in Parkinson's disease
    Lesniak, Robert K.
    Nichols, Robert Jeremy
    Smith, Mark
    Montine, Thomas J.
    FUTURE MEDICINAL CHEMISTRY, 2022, 14 (16) : 1167 - 1170